Claudia Brockmann

Dr. Claudia Brockmann

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2018 in Current Eye Research
Verified
Journal Article
Closed access
TBTobias Brockmann
Tobias Brockmann
DPDaniel Pilger
Daniel Pilger
CBClaudia Brockmann
Claudia Brockmann
AMAnna-Karina B. Maier
Anna-Karina B. Maier
EBEckart Bertelmann
Eckart Bertelmann
NTNecip Torun
Necip Torun
The purpose of this study is to identify predictors for the best-corrected visual acuity (BCVA), central corneal thickness (CCT), and the endothelial cell density (ECD) after primary Descemet's membrane endothelial keratoplasty (DMEK). In a prospective observational study, 108 eyes with Fuchs' endothelial dystrophy underwent a primary DMEK. Preoperative data, histologic parameters from host's Descemet's membrane, and follow-up data of the first eye were analyzed in regard to BCVA, CCT, and ECD, 12 months after surgery. Overall, 12 months postoperative, the BCVA improved to 0.11 ± 0.11 logMAR, the CCT declined to 529 ± 42 µm, and the ECD measured 1675 ± 418 cells/mm2. A significant influence of the preoperative CCT on postoperative BCVAs and CCTs was observed (r = 0.299, p = 0.014 and r = 0.507, p < 0.001, respectively). Especially eyes with a CCT <625 µm demonstrated a better BCVA (0.05 ± 0.07 logMAR) than eyes with a CCT ≥625 µm (0.13 ± 0.11 logMAR, p = 0.002). Furthermore, the identification of eyes with an early visual restitution was possible by considering follow-up data of the first eye. A preoperative CCT ≥625 µm was also sensitive to identify eyes with a persistent corneal swelling. The anterior banded layer thickness, which was obtained histologically, correlated to the preoperative CCT and the frequency of graft detachments (r = 0.601, p = 0.023 and r = 0.652, p = 0.041, respectively). Furthermore, a graft's baseline ECD ≤2100 cells/mm2 was found to be a risk factor for an ECD deterioration under 1000 cells/mm2 (1.8% vs. 15.8%, p = 0.020). Simple clinical parameters, such as the preoperative CCT, the course of visual restitution of the first eye, and the graft's baseline ECD, are efficient predictors for relevant outcome parameters after DMEK and therefore may be used for stratification. Furthermore, our findings indicate that a DMEK should be performed in eyes with Fuchs' endothelial corneal dystrophy, if possible, before the CCT exceeds 625 µm to maintain good clinical results.

25 June 2004 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
TLThomas Laube
Thomas Laube
CBClaudia Brockmann
Claudia Brockmann
RBRüdiger Buß
Rüdiger Buß
CLCarsten Lau
Carsten Lau
KHKerstin Höck
Kerstin Höck
HSHarald Schilling
Harald Schilling

30 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NFNicolas Feltgen
Nicolas Feltgen
TAThomas Ach
Thomas Ach
FZFocke Ziemssen
Focke Ziemssen
CQCarolin Sophie Quante
Carolin Sophie Quante
OGOliver Gross
Oliver Gross
ASAlexander K. Schuster
Alexander K. Schuster
Background: To investigate whether vaccination against SARS-CoV-2 is associated with the onset of retinal vascular occlusive disease (RVOD). Methods: In this multicentre study, data from patients with central and branch retinal vein occlusion (CRVO and BRVO), central and branch retinal artery occlusion (CRAO and BRAO), and anterior ischaemic optic neuropathy (AION) were retrospectively collected during a 2-month index period (1 June–31 July 2021) according to a defined protocol. The relation to any previous vaccination was documented for the consecutive case series. Numbers of RVOD and COVID-19 vaccination were investigated in a case-by-case analysis. A case–control study using age- and sex-matched controls from the general population (study participants from the Gutenberg Health Study) and an adjusted conditional logistic regression analysis was conducted. Results: Four hundred and twenty-one subjects presenting during the index period (61 days) were enrolled: one hundred and twenty-one patients with CRVO, seventy-five with BRVO, fifty-six with CRAO, sixty-five with BRAO, and one hundred and four with AION. Three hundred and thirty-two (78.9%) patients had been vaccinated before the onset of RVOD. The vaccines given were BNT162b2/BioNTech/Pfizer (n = 221), followed by ChadOx1/AstraZeneca (n = 57), mRNA-1273/Moderna (n = 21), and Ad26.COV2.S/Johnson & Johnson (n = 11; unknown n = 22). Our case–control analysis integrating population-based data from the GHS yielded no evidence of an increased risk after COVID-19 vaccination (OR = 0.93; 95% CI: 0.60–1.45, p = 0.75) in connection with a vaccination within a 4-week window. Conclusions: To date, there has been no evidence of any association between SARS-CoV-2 vaccination and a higher RVOD risk.

1 December 2016 in Retina
Verified
Journal Article
Closed access
CBClaudia Brockmann
Claudia Brockmann
MRMatus Rehak
Matus Rehak
JHJens Heufelder
Jens Heufelder
DCDino Cordini
Dino Cordini
TBTobias Brockmann
Tobias Brockmann
AHAnnette Hager
Annette Hager
Purpose: To identify predictors of treatment response by evaluating long-term outcomes of vasoproliferative retinal tumors after ruthenium-106 brachytherapy. Methods: In a retrospective case series, 39 eyes of 38 patients with vasoproliferative retinal tumors received ruthenium-106 brachytherapy between 2001 and 2013. Baseline clinical and morphologic parameters were analyzed regarding posttreatment tumor activity status. Results: Within a median follow-up period of 2.9 ± 2.9 years, overall, a tumor inactivation was achieved in 72% of cases and visual acuity remained stable in 69%. The mean apex dose was 90 ± 23 Gy (range, 51–140 Gy). Mean tumor thickness decreased significantly, from 2.9 ± 0.9 mm to 1.5 ± 1.0 mm (P < 0.001; paired t-test). Persistence or recurrence of tumor activity occurred in 28% of cases, requiring secondary intervention with intravitreal drug injections, vitrectomy, cryotherapy, or repeated brachytherapy. Comparison of inactive and active vasoproliferative retinal tumors revealed significant correlation between both initial basal tumour diameter and area and subsequent tumour activity status. In particular, a diameter >7.5 mm was associated with an 8-fold risk of persistent or recurrent activity, whereas basal area >40 mm2 demonstrated a 6-fold risk (P = 0.009 and 0.021, respectively; Fisher's exact-test). In contrast, tumor thickness was not found to be of prognostic relevance. Conclusion: Ruthenium-106 brachytherapy is an effective and safe therapeutic option for vasoproliferative retinal tumors. Additionally, tumor diameter and area are efficient predictors of persistence or recurrence of tumor activity.

16 May 2015 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
CBClaudia Brockmann
Claudia Brockmann
TBTobias Brockmann
Tobias Brockmann
SDSabrina Dege
Sabrina Dege
CBCatharina Busch
Catharina Busch
NKNorbert Kociok
Norbert Kociok
AJAntonia M. Joussen
Antonia M. Joussen

31 October 2020 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
CBClaudia Brockmann
Claudia Brockmann
JLJulia Löwen
Julia Löwen
SSShideh Schönfeld
Shideh Schönfeld
MRMirjam Rossel-Zemkouo
Mirjam Rossel-Zemkouo
ISIra Seibel
Ira Seibel
AJAntonia Joussen
Antonia Joussen
Aims: To investigate the retinal vascular structure and capillary anomalies of affected and fellow eyes of patients with unilateral Coats’ disease using multimodal imaging.Methods: Clinical investigation of both eyes of each patient with diagnosed Coats’ disease using ultra-widefield (UWF) fundus imaging, including UWF fluorescein angiography (UWFFA), spectral domain optical coherence tomography (OCT) and optical coherence tomography angiography (OCT-A).Results: We analysed 38 eyes of 19 patients with unilateral Coats’ disease and found that all fellow eyes (19/19; 100%) revealed vascular alterations, detected by UWFFA, predominantly located in the temporal periphery. Thereby, 89% of the fellow eyes (17/19) presented capillary bed abnormalities, that did not exceed the capillary level; 58% (11/19) presented tortuous abnormalities and 26% (5/19) presented microaneurysmatic abnormalities, exceeding the capillary level. If primarily affected eyes presented central Coats’ specific vascular abnormalities, fellow eyes revealed tortuous vascular abnormalities twice as often (78% (7/9) vs 40% (4/10); P=0.096). In primarily affected eyes, a tendency towards larger foveal avascular zones was revealed, compared to fellow eyes (0.28±0.16 mm2 vs 0.20±0.10 mm2; P=0.123).Conclusion: The use of modern multimodal imaging allows the detection of even subtle vascular changes in fellow eyes of patients with Coats’ disease. Coats’ disease appears to be a bilateral ocular disease with a predominant manifestation in one eye of the affected patients.